Literature DB >> 6283112

Establishment of infection by spleen necrosis virus: inhibition in stationary cells and the role of secondary infection.

I S Chen, H M Temin.   

Abstract

The relationship of two early events in the establishment of infection by avian retroviruses, the inhibition of viral DNA synthesis in stationary avian cells and the secondary infection which occurs after infection of replicating cells, was investigated. When neutralizing antibody to spleen necrosis virus was used to prevent secondary infection, the amount of unintegrated linear spleen necrosis virus DNA detected was much lower in infected stationary cells than in infected replicating cells. The amount of unintegrated linear spleen necrosis virus DNA in stationary cells was less than one copy per cell even at high multiplicities of infection. Viral DNA synthesis resumed after stimulation of the cells to replicate. The time of this viral DNA synthesis was closely correlated with renewed cellular DNA synthesis. In addition, blocking secondary infection of replicating cells prevented the rate of virus production from reaching the high levels usually associated with a normal productive infection by SNV. Virus production increased if secondary infection was allowed. However, this rise in virus production was not proportional to the amounts of viral DNA integrated after secondary infection.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6283112      PMCID: PMC256739     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Replication of reticuloendotheliosis viruses in cell culture: chronic infection.

Authors:  H M Temin; V K Kassner
Journal:  J Gen Virol       Date:  1975-06       Impact factor: 3.891

2.  Cell cycle-dependent activation of rous sarcoma virus-infected stationary chicken cells: avian leukosis virus group-specific antigens and ribonucleic acid.

Authors:  E H Humphries; H M Temin
Journal:  J Virol       Date:  1972-07       Impact factor: 5.103

3.  Carcinogenesis by RNA sarcoma viruses. XIV. Infection of stationary cultures with murine sarcoma virus (Harvey).

Authors:  R K Murray; H M Temin
Journal:  Int J Cancer       Date:  1970-05-15       Impact factor: 7.396

4.  Light inactivation of focus formation by chicken embryo fibroblasts infected with avian sarcoma virus in the presence of 5-bromodeoxyuridine.

Authors:  D Boettiger; H M Temin
Journal:  Nature       Date:  1970-11-14       Impact factor: 49.962

5.  Carcinogenesis by avian sarcoma viruses.

Authors:  H M Temin
Journal:  Cancer Res       Date:  1968-09       Impact factor: 12.701

6.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

7.  Stimulation by serum of multiplication of stationary chicken cells.

Authors:  H M Temin
Journal:  J Cell Physiol       Date:  1971-10       Impact factor: 6.384

8.  Reticuloendotheliosis virus nucleic acid sequences in cellular DNA.

Authors:  C Y Kang; H M Temin
Journal:  J Virol       Date:  1974-11       Impact factor: 5.103

9.  Replication of reticuloendotheliosis viruses in cell culture: acute infection.

Authors:  H M Temin; V K Kassner
Journal:  J Virol       Date:  1974-02       Impact factor: 5.103

10.  Requirement for cell division for initiation of transcription of Rous sarcoma virus RNA.

Authors:  E H Humphries; H M Temin
Journal:  J Virol       Date:  1974-09       Impact factor: 5.103

View more
  20 in total

1.  Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors.

Authors:  Grant Trobridge; David W Russell
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  Human foamy virus reverse transcription that occurs late in the viral replication cycle.

Authors:  A Moebes; J Enssle; P D Bieniasz; M Heinkelein; D Lindemann; M Bock; M O McClure; A Rethwilm
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection.

Authors:  D G Miller; M A Adam; A D Miller
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

4.  Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors.

Authors:  W A O'Brien; A Namazi; H Kalhor; S H Mao; J A Zack; I S Chen
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

5.  Diminished human immunodeficiency virus type 1 reverse transcription and nuclear transport in primary macrophages arrested in early G(1) phase of the cell cycle.

Authors:  N A Kootstra; B M Zwart; H Schuitemaker
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent.

Authors:  G M Springett; R C Moen; S Anderson; R M Blaese; W F Anderson
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation.

Authors:  A J Cann; J A Zack; A S Go; S J Arrigo; Y Koyanagi; P L Green; Y Koyanagi; S Pang; I S Chen
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

8.  Ty3 transposes in mating populations of yeast: a novel transposition assay for Ty3.

Authors:  P T Kinsey; S B Sandmeyer
Journal:  Genetics       Date:  1995-01       Impact factor: 4.562

9.  Human immunodeficiency virus type 1 DNA synthesis, integration, and efficient viral replication in growth-arrested T cells.

Authors:  G Li; M Simm; M J Potash; D J Volsky
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

10.  Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle.

Authors:  J A Zack; A M Haislip; P Krogstad; I S Chen
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.